S = selection of patients initiating semaglutide, tirzepatide, dulaglutide, or sitagliptin (as a placebo proxy) via propensity score 1:1 nearest neighbor matching to mimic randomization
Oversight: The Compounding Dilemma A central tension in the battle between compounding pharmacies and Big Pharma lies in the trade-off between access and safety is: access versus safety
The same central melanocortin activation that produces PT-141's effects occurs with Melanotan II, though the peptide also strongly activates tanning pathways
This is a pivotal moment for the food industry. Noting that 12% of the US population has tried the drugs, with 6% actively using them, Harold Schmitz at VC firm The March Group said the Ozempic era is helping to rejuvenate the foodtech space, which is now very much alive. Courtney McHugh, chief commercial officer at Amplifye, a UC Davis spinout with an enzyme that helps the body digest protein more effectively, added: Theres an entire secondary market that can come from any breakthrough technology. This is only the first generation of GLP-1 drugs and therefore the first generation of secondary markets, observed McHugh, who said GLP-1 drugs are driving interest in products that solve for energy levels, nutrient deficiencies, and gut issues. They are also prompting renewed interest in protein quality as well as quantity, she claimed
This is why we created the 10% Rule: we donate 10% of all our profits to veteran-focused charities in Glen's honor
Thus, we hypothesized that central GHSR drives binge-like alcohol drinking independently of peripheral ghrelin